Capsugel has announched the global commercial launch of its enTRinsic drug delivery technology platform, which provides enteric protection and targeted release of gastric acid- and heat-sensitive active ingredients to the upper gastrointestinal tract, without the need for functional coatings.

Capsugel's technology enables oral delivery of a variety of compounds, including vaccines, proteins and peptides, using pharmaceutically approved enteric polymers. The technology is globally available for customer projects following the successful completion of an 18-month lead-user customer-collaboration program that included feasibility studies with new and existing pharmaceutical products.

Customers can access the technology platform through a services agreement at Capsugel's locations in Ploërmel, France, and Bend, Oregon.

Source: Capsugel